Google
BCTXL 株価分析 — Briacell Therapeutics Corp. Warrant Expiring 2031
BCTXL に関するよくある質問
BCTXLの配当利回りは？
Briacell Therapeutics Corp. Warrant Expiring 2031の配当利回りは0.00%です。
BCTXLは今が買い時ですか？
当社AIのタイミングスコアは100点中1点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
BCTXL AI Analysis Summary
Our AI summary for BCTXL: Briacell Therapeutics Corp. Warrant Expiring 2031 (NASDAQ). The stock currently trades at a P/E of 0.00, a dividend yield of 0.00%. The AI Timing Score is 1/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.90
Price
0.04
(4.65%)
Day Change
|
|
|---|
Not enough data to analyze.
Loading chart...
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 77 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.90 |
| PBV / Sector |
0.32 / N/A
GREAT
|
| Earning Per Share | N/A |
| PE / Sector |
N/A / N/A
|
| PEG or PE/Growth / Sector |
N/A / N/A
|
| Average 1M Daily Value |
3863.811725000000
|
| Average 1W Daily Value |
3912.844900000000
|
| Timing Factors |
|
57% |
| Financial Health |
|
% |
| ポイントになる統計 |
|
% |
| 配当 |
|
% |
| 登録情報 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1
Phone: 604 921 1810
Website: https://briacell.com
Employees: -
Sector: -
Description: BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
